AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

URGN · NASDAQ · Biotechnology

UroGen Pharma (URGN)

Develops localized mitomycin therapies for low-grade urothelial cancers.

$40.38

vs last close−2.38 (−5.57%)

In millions of USD, except per-share figures

In millions	Q3 FY23Sep 2023	Q4 FY23Dec 2023	Q1 FY24Mar 2024	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Revenue	21	24	19	22	25	25	20	24	27	38	51	72
Cost of revenue	2	2	2	2	2	2	2	4	3	3	4	7
Gross profit	18	21	17	20	23	22	18	21	24	35	47	66
	32	36	43	45	40	50	55	62	52	54	67	66
Research & development	10	11	15	15	11	15	20	19	14	14	16	17
Selling, general & administrative	22	25	27	30	29	0	35	43	38	39	51	48
Other expenses	0	0	0	0	0	35	0	0	0	0	0	0
Operating income	−14	−15	−26	−26	−18	−28	−37	−41	−27	−19	−20	0
	−8	−8	−6	−8	−6	−7	−7	−7	−7	−8	−8	−9
Interest income	1	1	2	2	3	3	2	2	1	1	1	1
Interest expense	4	4	2	3	3	4	4	9	8	13	9	5
Other non-operating income	−1	−7	−2	4	−3	−1	2	8	−1	4	−1	4
Income before tax	−22	−22	−32	−33	−24	−35	−43	−49	−34	−27	−28	−9
Income tax expense	0	4	0	0	0	3	0	1	−1	0	−5	6
Net income from continuing operations	−22	−26	−32	−33	−24	−38	−44	−50	−33	−26	−24	−14
Net income	−22	−26	−32	−33	−24	−38	−44	−50	−33	−26	−24	−14
EPS, basic	−$0.68	−$0.72	−$0.97	−$0.91	−$0.55	−$0.80	−$0.92	−$1.05	−$0.69	−$0.54	−$0.47	−$0.28
EPS, diluted	−$0.68	−$0.72	−$0.97	−$0.91	−$0.55	−$0.80	−$0.92	−$1.05	−$0.69	−$0.54	−$0.47	−$0.28
Weighted average shares, basic	32	36	33	37	43	47	47	48	48	49	50	50
Weighted average shares, diluted	32	36	33	37	43	47	47	48	48	49	50	50
EBITDA	−12	−7	−24	−30	−15	−26	−39	−49	−26	−22	−19	−4
Depreciation & amortization	0	0	0	0	0	0	0	1	1	1	1	0
EBIT	−13	−8	−24	−30	−15	−27	−39	−49	−26	−23	−20	−4